MA-BRIGHTCOVE/SUNN-STRM
Brightcove (NASDAQ: BCOV), the world’s most trusted streaming technology company, today announced it has added Sunn Stream – a streaming service offering family-friendly movies, music and educational content – to its roster of media customers. Sunn Stream will rely on Brightcove’s two-time Emmy-award-winning platform to distribute its content to audiences nationwide.
Sunn Stream, currently in soft launch, is a streaming service that provides subscribers with personalized, family-friendly content, including movies, music, episodic shows, and educational videos on various topics. Using Brightcove’s reliable and scalable video technology, Sunn Stream will provide its audience with a seamless, curated, user-friendly experience across all devices.
“The streaming industry has clearly become more competitive, with providers striving to capture the attention and loyalty of more discerning audiences,” said Brightcove CEO Marc DeBevoise. “With this evolution, Sunn Stream has realized that it is essential to combine its unique content proposition targeted at a clearly-defined audience with the highest-quality video streaming and an intuitive, personalized user experience. Using our market-leading technology platform, Sunn Stream will be at the forefront of providing their customers with reliable, customized entertainment options, and will have access to best-in-class analytics to track performance.”
The popularity of independent media companies has continued to surge. As more consumers enter the fold, these entities increasingly require partners that can scale with them and ensure that customer experience remains a top priority. Sunn Stream tapped Brightcove’s industry-leading video-cloud streaming platform for its unique advantages, including unparalleled video quality, global scalability, unmatched customer support, and robust analytics.
“We’ve completely updated our Sunn Stream streaming service and app to make them easier to use so more customers can enjoy our films and shows,” said Sunn Stream Founder and President Garrett Z. Sutton. “Our curators will now handpick unexpected recommendations that our customers will love. And we’re more focused on creating an experience for the whole family that brings people together with laughter, tears, and thought-provoking moments.”
Sunn Stream joins a roster of media companies that rely on Brightcove to power their streaming capabilities, including FrightPix, The Academy of Motion Picture Arts and Sciences, Acun Medya, AMC Networks, BBC Studios, Canela Media, J.COM, MotoAmerica, REELZ, SBT TV, and SKY Mexico.
For more information, visit Brightcove.com.
About Sunn Stream
Sunn Stream is more than a streaming platform — it’s an Uncharted Entertainment and Educational Journey that takes users to bold, new worlds of cinema and television with family-friendly online content (movies, music and more) and a new Sunn Stream Film Festival (Coming Soon in 2025). As a modern-day storytelling campfire, it unites people through laughter, tears, and thought-provoking moments. This user-friendly platform delivers new narratives and experiences that appeal to multiple generations. Each month, Sunn Stream’s content curators handpick a collection of unexpected tales that ignite wonder, invite conversations and bridge hearts and minds. In addition to films and exclusive documentaries, this online platform offers quality educational content to fill voids left by public institutions such as financial education. Sunn Stream Members/ Subscribers will have unlimited access to new content that can ignite discussions with friends and family. Founded in 2022, Sunn Stream Founder/President, Bestselling Author and Entrepreneur Garrett Z. Sutton is dedicated to entertaining, educating and expanding horizons for users with new content that enhances lives. And Sunn Stream’s unique platform can be experienced online via SunnStream.com, Sunn Stream Productions App (iOS for iPads and iPhones, Apps for Android) and through Roku, Chromecast, and/or Apple TV devices. And when the credits roll, the journey is just beginning: https://sunnstream.com.
About Brightcove Inc.
Brightcove creates the world’s most reliable, scalable, and secure streaming technology solutions to build a greater connection between companies and their audiences, no matter where they are or on which devices they consume content. In more than 60 countries, Brightcove’s intelligent video platform enables businesses to sell to customers more effectively, media leaders to stream and monetize content more reliably, and every organization to communicate with team members more powerfully. With two Technology and Engineering Emmy® Awards for innovation, uptime that consistently leads the industry, and unmatched scalability, we continuously push the boundaries of what video can do. Follow Brightcove on LinkedIn, X, Facebook, Instagram, Threads, and YouTube. Visit Brightcove.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240716111027/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom